Clinical Trial Detail

NCT ID NCT03284385
Title Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

clear cell renal cell carcinoma

Therapies

Adavosertib

Age Groups:

No variant requirements are available.